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Abstract
Purpose of Review Hyperthermia is used to treat peritoneal surface malignancies (PSM), particularly during hyperthermic
intraperitoneal chemotherapy (HIPEC). This manuscript provides a focused update of hyperthermia in the treatment of PSM.
Recent Findings The heterogeneous response to hyperthermia in PSM can be explained by tumor and treatment conditions.
PSM tumors may resist hyperthermia via metabolic and immunologic adaptation. The thermodynamics of HIPEC are
complex and require computational fluid dynamics (CFD). The clinical evidence supporting the benefit of hyperthermia is
largely observational.
Summary Continued research will allow clinicians to characterize and predict the individual response of PSM to hyperther‑
mia. The application of hyperthermia in current HIPEC protocols is mostly empirical. Thus, modeling heat transfer with CFD
is a necessary task if we are to achieve consistent and reproducible hyperthermia. Although observational evidence suggests
a survival benefit of hyperthermia, no clinical trial has tested the individual role of hyperthermia in PSM.
Keywords Hyperthermia · Hyperthermic intraperitoneal chemotherapy · Peritoneal surface malignancy · Peritoneal
cancer · Cancer treatment · Thermodynamic model · Prognosis · Heat transfer · Survival

Introduction
Hyperthermic intraperitoneal chemotherapy (HIPEC) was
first introduced in clinical practice by Spratt in 1980 [1].
Since then, the use of hyperthermia as a therapeutic com‑
ponent for peritoneal surface malignancies (PSM) has been
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adopted globally [2]. The combination of chemotherapy and
hyperthermia has been proposed to eliminate microscopic
disease, not addressed by cytoreductive surgery alone, thus
improving the oncologic outcome of these patients [3]. In
addition to the pharmacokinetic advantage inherent to the
intracavitary delivery of cytotoxic drugs, which results in
regional dose intensification, hyperthermia has the added
advantage of direct cytotoxic effect on tumor cells [4••].
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The application of hyperthermia in HIPEC occurs
through the intraabdominal perfusion of heated fluid. A
machine, providing the flow and the heating mechanism,
recirculates the fluid between the inflow and outflow cath‑
eters. The perfusion of fluid can occur via the open coliseum
or closed techniques. In the open technique, the abdominal
wall is retracted, a tent is developed to accommodate the
fluid, and the chemotherapeutic agent is uniformly exposed
to all anatomical structures by continuous manual stirring
by the surgeon [5]. In the closed technique, the inflow and
outflow catheters are placed in the abdominal cavity and
the skin is sutured tightly to ensure an adequate seal prior
to circulating the chemotherapeutic drug using a perfusion
machine [6].
Despite its widespread acceptance, there is great variabil‑
ity in the protocols and techniques used for HIPEC [2]. In
recent years, the results of randomized controlled trials have
questioned the therapeutic benefit of HIPEC after complete
surgical cytoreduction [7••, 8••]. However, it is still unclear
whether these results are due to cancer-specific sensitivi‑
ties, choice of chemotherapeutic agent, inadequate thermal
exposure, or application of the protocol. The present review
aims to provide a focused update of the current knowledge
of hyperthermia in PSM, understand heat transfer and its
clinical consequences during HIPEC, and review the most
recent clinical studies.

The Cellular Response to Therapeutic
Hyperthermia in Peritoneal Surface
Malignancies
It is well known that elevated temperatures alone, by cause
of protein denaturation and aggregation, can induce cell
death. As described by Dewey, the survival of cell lines
at temperatures above 43°C follows a straight line in an
Arrhenius plot, indicating a dose-dependent relationship
between temperature and time on survival. A biphasic plot
was observed below this threshold, indicating the develop‑
ment of thermotolerance [9]. Based on these observations,
equivalent thermal damage can be estimated as the thermal
isoeffect dose, such as the cumulative equivalent minutes at
43°C [10]. Ultimately, cell death occurs early due to apop‑
tosis or later due to necrosis, cell-cycle arrest, and loss of
clonogenicity [11]. Because cancer cells are known to be
more susceptible to thermal cytotoxicity than normal human
cell lines [12], therapeutic hyperthermia can be exploited in
patients with cancer.
The cellular response to non-lethal hyperthermia is
largely governed by heat-shock proteins (HSP) [13]. Fol‑
lowing heat exposure, heat-shock factor 1 is liberated from
HSP70 and HSP90 (which are recruited to stressed pro‑
teins) and forms oligomers that bind more avidly to the heat
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shock element, increasing the expression of HSP [13, 14].
Elevated levels of HSP-70 and HSP-90 are demonstrated
both in stomach cancer cells and in the serum of patients
undergoing HIPEC for stomach cancer [15]. Among a vast
array of functions, the HSP network works in the unfolding
and refolding of stress-denatured proteins, regulation of the
cell cycle, proliferation, and apoptosis [16]. In this manner,
HSPs can prevent irreversible protein aggregation and cell
death secondary to heat exposure and are widely regarded
as targets for antitumor therapies [13, 17].
The expression of HSPs can also modulate the immune
system. Akyol et al. demonstrated elevated levels of HSP10
in the serum of ovarian cancer patients, which inhibited the
expression of CD3-zeta and prevented the activation of T
cells [18]. When released into the circulation, HSPs can
also be presented to dendritic cells (via CD91) and induce
a Th1-like response against cancer [19]. Finally, Sedlacek
et al. showed that HSP gp96 activates NK cells, inducing a
phenotype of increased cytokine production [20].
The PSM comprise a histologically heterogeneous group
of cancer cell lines with various origins, including gastric,
colorectal, ovarian, uterine, mesothelial, and appendi‑
ceal [21]. As thermal sensitivity varies between cell lines
[22–24], a single thermal isoeffect dose is unlikely to be
effective for all. Indeed, it has been pointed out that the
biological rationale of temperatures and heating periods in
HIPEC is lacking [4••, 24], stressing the need for continued
research.
In a recent study, Helderman et al. used human colorectal
cancer cell lines and exposed them to increasing tempera‑
tures with and without chemotherapy [4••]. The in vitro
studies showed a dose-dependent relationship between
temperature and decreased cell viability at 48 hours, and
decreased clonogenic activity at 10 days following 60 min‑
utes of treatment, particularly with temperatures of at least
41°C. Likewise, Bespalov et al demonstrated that hyperther‑
mia at 41°C improved the survival of female Wistar rats who
were inoculated with ovarian cancer cells, increasing their
life expectancy by 14 days [25].
Although hyperthermia can alone produce cell death, the
most important purpose of hyperthermia in current HIPEC
protocols is chemosensitization. In vitro studies show that
the effect of platinum-based agents is temperature depend‑
ent, with increasing levels of apoptosis and a predominant
arrest of all cell lines in the G1 and G2 phases [9]. Pharma‑
cokinetic studies demonstrate that hyperthermia increases
the concentration of chemotherapeutic agents in intraab‑
dominal tissues and the rate of systemic absorption, with no
significant changes in the maximum systemic concentrations
[26, 27••].
Unfortunately, thermal enhancement is not uniform
across chemotherapeutic agents or cells. For instance, Hel‑
derman et al. observed that while temperature-dependent
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synergy occurred with platinum-based drugs (e.g., oxali‑
platin, cisplatin, and carboplatin), colorectal cancer cells
were equally susceptible to mitomycin or 5-FU, regardless
of hyperthermia [4 ••]. In another study, de Bree et al.
cultured ovarian cancer (SKOV-3, OVCAR-3) cells and
exposed them to paclitaxel and docetaxel in conditions
of normothermia (37°C) or hyperthermia (41.5°C) [24].
Exposure of SKOV-3 cells to hyperthermia only resulted
in thermal enhancement at 24 hours, with no differences at
7 days. In contrast, OVCAR-3 cells had a higher prolifera‑
tion rate at 24 hours, but evidence of thermal enhancement
at 7 days. Interestingly, OVCAR-3 cells exposed to 2h of

hyperthermia alone showed a trend toward increased pro‑
liferation at 7 days.
Atallah et al. exposed ovarian (IGROV-1) and colon can‑
cer (Caco-2, HT-29) cells to oxaliplatin alone or in combi‑
nation with 1h of hyperthermia at 42°C [22]. Hyperthermia
effectively decreased the dose to achieve 50% growth inhi‑
bition across all cell lines by several orders of magnitude.
Notably, while IGROV-1 cells arrested in G1 phase (via p53)
or G2-M phases (upregulation of cyclins A and B), HT-29
cells arrested in mid-G1 (via ckd2 inhibition).
Several mechanisms of resistance to hyperthermia have
been elucidated recently (Table 1). Kanamori et al. found

Table 1  Potential Mechanisms of Resistance to Therapeutic Hyperthermia in PSM Cell Lines
Author, year

Cell line

Type of cancer Hyperthermia exposure

Mechanism(s) of resistance

Tu et al., 2018 [15]

SGC7901

Gastric

41° C for 60 mins

Tu et al., 2018 [15]

AGS

Gastric

41° C for 60 mins

Cesna et al., 2019 [28]

OVCAR-3

Ovarian

43° C for 60 mins

Overexpression of HSP90
(stabilizes proteins for cell
development, growth, and
survival).
Overexpression of HSP70
(interferes with apoptosis).
Overexpression of HSP90
(stabilizes proteins for cell
development, growth, and
survival).
Overexpression of HSP70
(interferes with apoptosis).
Heme-oxygenase 1 prevents
free heme from sensitizing
cells to undergo apoptosis.
Stimulation of glutamine
dehydrogenase (metabolic
adaptation)
Downregulation of glycolytic
pathways and upregulation
of mitochondrial pathways
(metabolic adaptation)
Overexpression of HSP27 ➔
reduced expression of Bax
and Caspase-3 ➔ increased
Bcl-2 ➔ reduced apoptosis.
Expression of HSP10 inhibited
CD3-zeta, preventing T-cell
activation.
Expression of HSP110 and
increased cell proliferation.
Upregulation of CTGF and
modulation of glycolysisrelated genes.
Activation of CXCR4 (prolif‑
eration) through mesenchy‑
mal stem cell secretion of
CXCL12.
CDK6 upregulation via
hyperthermia-induced AKT
inhibition, resulting in
decreased apoptosis.

Sukovas et al., 2019 [29]
Kanamori et al., 2021 [30•]

40, 43° C for 60 mins
SKOV-3

Ovarian

Kong et al., 2020 [31]

46° C for 60 mins

37, 39, 41, 43, 45° C for 60
mins

Akyol et al., 2006 [18]

Immune Function Study

Ovarian

No exposure

Kimura et al., 2017 [32]

MKN45

Gastric

43° C for 180 mins

Hatakeyama et al., 2016 [33] SKOV3, HeyA8, ES2, and
KLE

Ovarian

46° C for 60 mins

Lis et al., 2011 [34]

SKOV3/CAOV3

Ovarian

42° C for 60-120 mins

Liu et al., 2021 [35]

SH-10-TC, HGC-27

Gastric

42° C for 120 mins
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that hyperthermia-resistant SKOV-3 cells responded to
hyperthermia by downregulating glycolytic pathways (via
ubiquitination of PKM 1/2) and sustaining ATP production
by upregulating mitochondrial activity [30•]. In OVCAR-3
cells, metabolic adaptation to hyperthermia may occur via
stimulation of glutamine dehydrogenase [29]. SKOV-3 cells
can also resist hyperthermia-induced apoptosis via HSP27,
which in turn promotes Bcl-2 expression and inhibits the
expression of Bax and Caspase-3 [31]. In vitro studies sug‑
gest a variable expression of heme-oxygenase 1 among cell
lines and that silencing heme-oxygenase 1 activity results in
decreased cell viability of ovarian cancer cells (OVCAR-3),
but not in gastric cancer cells (AGS) [28].
Hyperthermia can also exert indirect effects by modu‑
lating the immune response. For instance, 2 hours of mild
preoperative hyperthermia (39°C) in patients undergoing
colorectal surgery increased the levels of HSP60, 70, and
90, while ameliorating increases in TNF-α and procalcitonin
[36]. Others have documented an increased antigen-specific
cytokine response in T cells [37], and an enhanced IL-2
production by CD4 T-cell activation [38]. In contrast, Ahl‑
ers et al. showed that after 1 hour of whole-body radiant
hyperthermia at 42°C, the populations of NK cells and γδ
T cells increased, while the number of T cells decreased. In
addition, the serum levels of IL-12 and INF-γ/IL-10 ratio
decreased [39]. In patients undergoing HIPEC, Roth et al.
found that longer durations of hyperthermia (60 and 90 min‑
utes vs. 30 minutes) led to a secondary peak in CRP levels
between postoperative days 5 and 8 [40].

Heat Transfer During HIPEC
In this section, we begin with the underlying physical prin‑
ciples necessary to comprehend and properly model HIPEC.
Some of the limitations of the models used to describe the
physical processes behind will be highlighted. From the
physical point of view, an understanding of HIPEC requires
connecting principles of heat transfer and fluid dynamics.
Physical models of this process have been proposed in the
literature [41–43], as well as experimental measurements of
temperature distribution [44], the effect of high flow rates
[45], and intraabdominal pressures during HIPEC [46].
The body temperature depends on the heat exchange during
the surgery. The heat gained is heat transferred by the heated
fluid and that due to the production from the metabolism.
The first can be calculated with the input flow rate (assum‑
ing steady-state flow, no accumulation) and the inflow and
outflow temperatures; the second one is primarily a func‑
tion of the mass of the patient. The heat loss comes from
mechanisms of energy transfer (radiation, convection, and
conduction), as shown in Fig. 1A. Evaporative heat losses
are negligible in the context of a closed HIPEC [43]. The heat
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loss by radiation, conduction, and convection is all roughly
proportional to the surface area of the body, the skin, and the
surrounding temperature. Because for radiation the rate of
heat gain or loss is proportional to the fourth power of the
absolute temperature of the skin (or clothing) minus the fourth
power of the surrounding temperature, radiation is dominant
in heat exchange when the temperature difference exceeds a
few degrees (6°-10°) [47]. A complete quantitative analysis of
the heat exchange is a formidable task since it is necessary to
know various parameters, including air velocity, air humidity,
barometric pressure, the contact area with the materials in the
operating room, the thermal conductivity of these materials,
etc., parameters generally not reported in the literature.
On the back of such concerns, one can focus on modeling
the heat exchange in the abdominal cavity [42, 48••]. In a
simplified way, a four-compartment model can be employed,
with the four compartments being the organs, the peritoneal
wall, the chemotherapeutic hot fluid, and the blood volume,
as shown in Fig. 1D. The compartments exchange heat only
through conduction and convection. A simplified model of
the abdominal cavity was considered to simulate the inflow
and outflow temperatures by Ladhari et al. [42] Recently, a
more realistic model of the heat exchange in a rat was pre‑
sented by Loke et al. [48••].
Temperature changes in a cross section of tissue vary
according to the position and the sinusoidal heat flux cre‑
ated by the blood flow, as proposed by the Pennes equation.
This equation is of common use in other models of thera‑
peutic hyperthermia, such as the radiofrequency ablation of
tumors [49]. To model the circulating hot fluid in the cavity,
it is mandatory to use the Navier–Stokes equations, which
describe a continuum of moving fluid and include other
parameters such as pressure and velocity. Although exact
solutions to the Navier–Stokes equations have only been
obtained in particular cases, the problem can be numeri‑
cally approximated using computational fluid dynamics
(CFD). This area has recently seen significant advances,
including the development of CFD software to simulate the
dynamic flow, temperature, and drug distribution during
HIPEC [48••, 50, 51]. Studies in rats have demonstrated
that maximizing the distance between in- and outflows and
adding multiple catheters leads to increased temperature
homogeneity and stability [43, 48••, 52]. Moreover, a homo‑
geneous distribution of temperature can be achieved when
the abdomen is maximally distended and a high flow rate is
maintained [44, 45, 48••].
The complexity of the CFD model required the use of vari‑
ous assumptions, such as a laminar flow and a temperatureindependent fluid density [48••]. Because of the geometry of
the flow region, the presence of obstacles, the manual shak‑
ing of the abdomen, and the gravitational effects, the use of
a turbulence model is advised. Naturally, this entails consid‑
erable computation time. Finally, large vessels passing near
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Fig. 1.  Schematic Representation of the Thermodynamic Model for
Closed HIPEC. (A) The human silhouette shows an inflow catheter
with a temperature TInflow and an outflow catheter with a temperature
TOutflow, as well as the heat exchange with the fluid and the environ‑
ment. HRadiation, HConvection, and HConduction are the heat current of radi‑
ation, convection,
(
) and conduction, respectively. All three are propor‑
tional to TSn − TAn with n = 1 for conduction and convection and n = 4
for radiation, where TS and TA are the skin (superficial) temperature

and ambient temperature, respectively. HFluid and HMetabolic are the
heat current transferred by the fluid and that due to the metabolism,
respectively. In the abdominal cavity, the fluid flow (B) and temper‑
ature distribution (C) are pictured for illustrative purposes only; the
directions and numbers are not suitable for interpretation. (D) A com‑
partment model of the abdominal cavity. The arrows indicate where
heat is exchanged by convection and conduction. Image created with
Biorender®.

or through the intraabdominal cavity can conduct heat loss
causing heterogeneities in temperature distribution [53–55].
These vessels can act as heat exchangers between the blood
and the intraabdominal cavity during HIPEC and should also
be included in future models of hyperthermia in HIPEC.
Because the tissues are poor conductors of heat, tissues
outside of the abdominal and pelvic cavities (e.g., the brain,
the extremities) gain heat primarily via the blood vessels
[56]. Thus, the rate of heat transfer in the body is dictated
by the blood flow, which could help predict overheating.
Poiseuille’s law shows that blood flow increases as blood
viscosity decreases, assuming a constant blood pressure dur‑
ing surgery. Experimentally, it has been observed that blood
viscosity increases as hematocrit increased and as tempera‑
ture decreased [57–59]. Consequently, blood temperature
and hematocrit determine the resistance to blood flow and
limit the rate of heat transfer out of the abdominal cavity.

Finally, the thermal conductivity of the tissues needs to be
considered. For instance, the fatty tissue has a low thermal
conductivity and likely interferes with heat transfer in obese
people, acting as an insulating barrier [60]. Moreover, both
blood flow and temperature affect the thermal conductivity
in living tissues [47, 61]. As thermal conductivity increases
linearly with temperature [61], future research would benefit
to consider such changes in future models.

Clinical Measurements During Hyperthermia
in Humans
The physiological response to intraabdominal hyperthermia
has several components. Intraoperatively, the hemodynamic
response is characterized by increased cardiac index, heart
rate, and central venous pressure, along with a decreased
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stroke volume variation [62, 63]. Owing to vasodilatation
and a decreased blood viscosity, a reduction in systemic vas‑
cular resistance has also been observed [64•]. Within studied
parameters, changes in the intraabdominal pressure (8-12 vs.
18-22 mmHg) seem to only affect the central venous pres‑
sure [63]. As reported by Reis et al., high intraabdominal
pressures (but not temperature) caused an increase in peak
inspiratory pressure [63]. Moreover, patients may experi‑
ence metabolic changes associated with the degree of hyper‑
thermia. In a study by Ceelen et al., a linear relationship
was found between the area under the curve of temperature
and the changes in glucose, sodium, and lactate levels, with
near significant changes for bicarbonate levels [65]. Finally,
because HIPEC occurs several hours after the beginning
of anesthesia, the thermodynamic state at the beginning of
perfusion assumes that heat redistribution from core to the
periphery has stabilized [66].
According to Rettenmaier et al., the temperature of the
intraabdominal fluid demonstrates an initial gain of ~1°C
during the first 15 minutes of HIPEC and remains constant
thereafter [44]. As such, while inflow temperatures in their
study were maintained at 42.5°C, outflow temperatures
increased from 41 to 42°C. Accordingly, all percutaneously
placed intraabdominal temperature probes (upper, midline,
and suprapubic quadrants) showed a ~1°C temperature
increase from their respective baseline prior to stabilizing,
in line with the inflow/outflow temperature gradient.
Despite a relatively constant fluid temperature, other
measures of hyperthermia are highly variable in clinical
conditions. Hendrix et al. studied a total of 135 subjects
undergoing CRS/HIPEC [67•]. Their 90-minute HIPEC
protocol included a starting mean core-body temperature
(CBT) of 36.7°C, mean perfusion flow of 2.35 L/min, and
target outflow and intraperitoneal temperatures of ≥40°C
and 40-42°C, respectively. Overall, the sample achieved
maximum temperatures between 37.5 and 40.1°C. About
half of the patients (56%) achieved temperatures of 38.539.5°C, while only 27% were above 39.5°C. Goldenshluger
et al. reported a study of 115 patients undergoing CRS/
HIPEC via the closed-abdomen technique, using a volume
of 3-5 L of solution and an inflow temperature of 44°C to
achieve a mean inflow/outflow of 41.7°C for 60-90 minutes.
The authors reported a mean bladder temperature of 38.1°C
±0.9°C and mean CBT of 37.5°C ±0.7°C, with no patients
exceeding 40°C [68].
A major obstacle to predicting the development of hyper‑
thermia is the heterogeneity of HIPEC protocols in current
practice. In a recent systematic review, Yurttas et al. dem‑
onstrated that exposure times among the 171 reports ana‑
lyzed varied between 20 and 120 minutes, with perfusate
volumes between 2 and 6, closely related to the technique
used (open vs. closed) [69 ••]. Regarding hyperthermia,
studies mostly reported inflow temperatures of 42°C, while
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intraabdominal temperatures ranged anywhere from 38.5°C
to 44°C. In the study of Hendrix et al., patients experienc‑
ing core-body hyperthermia of at least 39.5°C had a lower
BMI (25.3 vs. 28.2 Kg/m2, p=0.03) and suffered less fre‑
quently from hypertension (25 vs. 46%, p=0.03). Recently,
we performed an analysis of 214 patients undergoing CRS/
HIPEC to determine the predictors of bladder hyperthermia
according to several prespecified definitions [70•]. Overall,
the incidences of mild (T≥38°C) and moderate-to-severe
(T≥39°C) hyperthermia were 53.27% and 6.54%, respec‑
tively. After multivariate analysis, independent predictors
for hyperthermia included age (OR=0.968, 95% CI 0.9450.992, p=0.01), BMI (0.953, 95% CI 0.913-0.995), female
gender (OR=0.208, 95% CI 0.108-0.403), type of chemo‑
therapy (cisplatin vs mitomycin, OR=0.235, 95%CI 0.1040.503, p=0.036), and duration of chemotherapy (OR= 1.094,
95%CI 1.018-1.177).

The Clinical Role of Hyperthermia in PSM
In the treatment of PSM, hyperthermia has been largely
judged by the overall impact of HIPEC on survival out‑
comes. Because PSM is a group of diseases, differences
in the median overall survival (OS) in patients undergoing
CRS/HIPEC are best understood by the primary histology
of the tumor. In a large cohort study by Kyang et al., median
OS was reported to be 30, 35, 60, 63, and 248 months for
ovarian, colorectal, mesothelioma, high-grade appendiceal,
and low-grade appendiceal carcinomas, respectively [71].
Considerable evidence supports the benefit of CRS/
HIPEC over systemic therapy in selected surgical candidates
[72–75]. In a landmark study, Verwaal et al. randomized
105 colon cancer patients to either CRS/HIPEC or systemic
chemotherapy and found that CRS/HIPEC significantly
improved OS (HR= 0.55, 95% CI 032-0.95; p=0.032), pro‑
longing the median OS by 10 months [76••]. Robust obser‑
vational data support CRS/HIPEC for PSM of appendiceal
etiology [77•]. For malignant peritoneal mesothelioma, a
pooled analysis of 1047 patients (20 studies) reported OS
of up to 92 months [74]. Finally, better OS rates (HR=0.61,
95% CI 0.41-0.76; p<0.01) have been shown in patients with
PSM secondary to ovarian cancer that receive HIPEC in
addition to CRS with or without systemic therapy, particu‑
larly in studies with larger sample sizes, longer durations of
hyperthermia, and CRS/HIPEC followed by chemotherapy
[75].
Just recently, experimental studies started to address the
independent effect of HIPEC in patients undergoing CRS.
Table 2 describes the HIPEC protocols, and the measures of
hyperthermia published in comparative trials. In the COLO‑
PEC trial, 202 patients with perforated colon cancer were
randomized to receive CRS and adjuvant chemotherapy with

Sample Size

105

202

150

265

71

Author, Year

Verwaal et al., 2003
[76••]

Klaver et al., 2019
(COLOPEC) [8••]

Goere et al., 2020
(PROPHYLOCHIPPRODIGE 15) [78]

Quenet et al., 2021
(PRODIGE 7) [7••]

Antonio et al., 2021
(CARCINOHIPEC)

Ovarian Cancer

Colorectal Cancer

Colorectal Cancer

Colorectal

Colorectal

Open

Open and closed.

Open

Open and closed.
Single, multiperforated
inflow and outflow
catheters.

Open

Primary Tumor Histology HIPEC
Technique

Type of fluid: Dialysis
Volume: 3L.
Flow: 0.5-0.7 L/min
Duration: ≥60 min.
Chemotherapy: Cisplatin

Type of fluid: Dextrose
Volume: 2L/m2.
Flow: Not reported
Duration: 30 min.
Chemotherapy: Oxali‑
platin

Type of fluid: Dextrose
5%
Volume: 2L/m2
Flow: Not reported
Duration:30 min
Chemotherapy: Oxali‑
platin

Type of Fluid: Isotonic
Dialysis.
Volume: ≥2L.
Flow: 1-2 L/min.
Duration: 30 min.
Chemotherapy: Oxali‑
platin

Type of fluid: Isotonic.
Volume: 3 L.
Flow: 1-2 L/min.
Duration: 90 min.
Chemotherapy:
Mitomycin C.

Perfusion Parameters

Table 2  Protocols and Measures of Hyperthermia in Comparative Phase III Trials of HIPEC in PSM
Main Results

Not reported.

Not reported

Not reported.

Inflow T: Not reported.
Physical measures and
Outflow T: Not reported.
intravenous fluids.
Intraabdominal T: Goal
of 42-43°C
CBT: Goal to maintain an
esophageal temperature
of 37°C.
Other sites of tempera‑
ture: Not reported

Inflow T: 43°C
Outflow T: Not reported
Intraabdominal T: Not
reported
CBT: Not reported
Other sites of tempera‑
ture: Not reported

Inflow T: 45°C
Outflow T: 42-42.5°C
Intraabdominal T: 43°C
CBT: Not reported
Other sites of tempera‑
ture: Not reported

Inflow T: 42-43°C
Outflow T: Not reported
Intraabdominal T: Not
reported
CBT: Not reported
Other sites of tempera‑
ture: Not reported

RFS was improved by
HIPEC, HR=0.12, 95%
CI 0.02-0.89; p=0.038 in
multivariate analysis.
OS at 5 years: 45%
(HIPEC) vs. 25% (Con‑
trol).

No difference in median
OS (41.7 vs. 41.2
months, p=0.99,
HR=1.00, 95% CI 0.631.58) or RFS (13.1 vs.
11.1 months, p=0.43,
HR= 0.91, 95% CI 0.711.15).

3-year RFS was 53% in the
surveillance group vs.
44% in second look +
HIPEC (HR=0·97, 95%
CI 0·61–1·56; p=0·82).

No difference in RFS
(80.9% vs. 76.2%,
p=0.28) at 18 months.

Inflow T: 41-42°C
HIPEC reduced the risk of
Inflow temperature
Outflow T:
death (HR=0.55, 95% CI
adjusted if CBT >39°C.
Intraabdominal T: ≥40°C Other management strate‑
0.32-0.95; p = .032) at a
CBT: Not reported
gies were not reported.
median follow-up of 21.6
Other sites of tempera‑
months.
ture:
Not reported

Measures of Temperature Intraoperative Manage‑
ment of Hyperthermia
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CBT: Core-body Temperature. CI: Confidence Interval. HIPEC: Hyperthermic Intraperitoneal Chemotherapy. HR: Hazard Ratio. OS: Overall survival. RFS: Recurrence-free survival.

RFS for HIPEC was better
(HR=0.66, 95% CI 0.50.97; p=0.003).
OS for HIPEC was better
(HR=0.67, 95% CI 0.480.94; p=0.02).
Not reported.
245
van Driel et al., 2018
[80•]

Ovarian Cancer

Open

Type of fluid: Not speci‑
fied.
Volume: Variable (ensure
adequate exposure).
Flow: 1 L/min (adjusted
if intraabdominal T
<40°C.
Duration: 90 min.
Chemotherapy: Cisplatin.

Inflow T: 41-42°C.
Outflow T: 40°C.
Intraabdominal T: 40°C
CBT: Not reported
Other sites of tempera‑
ture: Not reported.

RFS for HIPEC was similar
(HR=1.49, 95% CI 0.962.32; p=0.076)
OS for HIPEC was similar
(HR=1.33, 95% CI 0.692.56; p=0.39)
Not reported.
Inflow T: 41-43°C.
Outflow T: Not reported.
Intraabdominal T: Not
reported
CBT: Not reported
Other sites of tempera‑
ture: Not reported
Type of fluid: Normal
Saline.
Volume: 3L.
Flow: Not reported
Duration: 90 min.
Chemotherapy: Carbo‑
platin.
Closed
98
Zivanovic et al., 2021
[79]

Ovarian Cancer

Sample Size
Author, Year

Table 2  (continued)

Primary Tumor Histology HIPEC
Technique

Perfusion Parameters

Measures of Temperature Intraoperative Manage‑
ment of Hyperthermia

Main Results
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or without the administration of HIPEC [8••]. The primary
outcome was defined as the peritoneal metastasis-free sur‑
vival at 18 months after surgery. No significant differences
were noted between the two groups (69 vs. 69.3%, p=0.99).
Because the protocol allowed for HIPEC to occur at the time
of surgery or at 5-8 weeks, many patients in the experimen‑
tal group had evidence of peritoneal metastasis prior to
receiving adjuvant HIPEC. Addressing these limitations,
the PRODIGE-7 trial randomized 265 patients to either
CRS alone or CRS/HIPEC [7••]. Again, the authors did not
identify differences in the OS between the two groups (HR=
1·00, 95% CI 0·63–1·58; p=0.99), prompting them to not
recommend the use of HIPEC in this population. However,
critics of this trial contend that the duration of HIPEC (30
minutes of oxaliplatin) administered may have contributed to
the lack of improvement in survival. This criticism is further
strengthened by the fact that when patients were stratified by
PCI (peritoneal carcinomatosis index); the cohort of patients
with a PCI of 11-15 did have an improvement in overall
survival in comparison with patients who did not receive
hyperthermic intraperitoneal chemotherapy (41.6 months vs
32. 7 months, p=0.021).
Conflicting results have been reported in ovarian cancer.
In the CARCINOHIPEC trial, Antonio et al. randomized
79 women with PSM secondary to ovarian cancer to CRS
alone or with cisplatin HIPEC [81]. Multivariate analysis
suggested that the risk of recurrence was reduced in patients
receiving HIPEC (HR= 0.12, 95% CI 0.02-0.89; p=0.038).
In contrast, Zivanovic et al. could not demonstrate a superior
treatment strategy between CRS with or without carbopl‑
atin HIPEC [79]. In a recently published RCT by van Driel
et al., the addition of HIPEC to cytoreductive surgery in
patients with stage III ovarian cancer showed an improve‑
ment in both recurrence free (14.2 months vs 10.7 months)
and overall survival (45.7 months vs 33.9 months) compared
to cytoreductive surgery alone at a median follow-up of 4.7
years [80•].
To date, no experimental study has addressed the inde‑
pendent effect of temperature in the prognosis of patients
with PSM. As a secondary outcome, our group analyzed a
sample of 214 patients undergoing CRS/HIPEC [70•]. Our
results showed that OS and recurrence-free survival curves
were consistent with the primary tumor histology. Interest‑
ingly, we found that the lack of mild hyperthermia (≥38°C)
at the end of perfusion was independently associated with
worse recurrence-free and overall survival. Moreover, a
trend toward improved survival was noticed for patients who
achieved bladder hyperthermia for at least 30 minutes during
perfusion [70•].
Concerning safety, the evidence from clinical trials is
conflicted by the presence of chemotherapy and the impli‑
cations of major abdominal surgery. For instance, staged
HIPEC alone had a lower complication rate and a shorter
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length of stay than simultaneous HIPEC in the COLOPEC
trial [8••]. Moreover, the PRODIGE-7 trial demonstrated
that the length of stay and the interval between surgery and
food intake were longer in those undergoing CRS/HIPEC
versus CRS alone. Although the incidence of grade 3 or
higher adverse events was higher in the CRS/HIPEC group,
individual differences were only significant for hematologi‑
cal events such as neutropenia and thrombocytopenia. Nei‑
ther Antonio et al. or Zivanovic et al. observed differences in
the short-term postoperative outcome of women undergoing
CRS/HIPEC for ovarian cancer [79, 81]. Finally, Koole et
al. did not find significant differences in the quality of life
between patients randomized to CRS alone or CRS/HIPEC
[82].
Few observational studies have addressed the independ‑
ent effect of hyperthermia in postoperative complications.
Hendrix et al. found that elevated core-body temperatures
(defined as ≥39.5°C) were associated with a higher risk
of 30-day postoperative complications (OR=3.77, 95% CI
1.56-9.14) [67•]. For Goldenshluger et al., each Celsius
degree increase in CBT raised the odds of postoperative
complications by more than two-fold (OR 2.68, 95% CI
1.2–6.01, p = 0.02) [68]. In contrast, our study showed that
bladder hyperthermia was not an independent risk factor of
30-day complications [70•]. In a propensity score-matched
study, Gremonprez et al. analyzed the postoperative outcome
of 90 colorectal cancer patients undergoing CRS with either
normothermic (n=45) or hyperthermic (n=45) intraperito‑
neal chemotherapy [83]. Overall, the differences in major
postoperative morbidity at 30 days between the HIPEC and
normothermic groups did not reach statistical significance
(35.6% vs. 26.7%, p=0.362).

Conclusion
Patients with PSM receive therapeutic hyperthermia in the
context of HIPEC. Although hyperthermia induces and
enhances cellular death [9, 22, 26], cancer cells can resist it
through HSP upregulation [13], metabolic adaptation [30•],
and modulation of the immune system [39]. Because the
response to hyperthermia (at the temperatures administered
in HIPEC) is variable, clinical practice will benefit from
molecular markers that predict the individual response to
therapy.
Unlike a well-circumscribed tumor, the residual disease
of PSM is invisible when the patient has undergone an opti‑
mal cytoreduction. As a result, applying thermal dosimetry
principles to HIPEC is problematic. While the intraabdomi‑
nal fluid temperature is relatively constant, heat uptake is
variable and depends on patient variables and the perfu‑
sion protocol. Thus, we need better indicators of adequate
heat transfer to the tissues, such as the core-body or bladder

temperatures. To understand the role of hyperthermia in
PSM, we need a better ability to model hyperthermia dur‑
ing HIPEC, so that clinical trials can adequately test specific
temperature, goals, and outcomes.
Despite the existing gaps in knowledge, the growing body
of literature is encouraging. HIPEC is being increasingly
evaluated for PSM secondary to stomach [84, 85], pancre‑
atic [86], and hepatobiliary [87] malignancies. As the use of
computational fluid dynamics and thermodynamic models
improves our understanding of hyperthermia [42, 43, 48••],
the inclusion of real-world data will allow such develop‑
ments to individualize therapy and increase its margin of
safety. New clinical trials are underway, including those test‑
ing the individual effect of hyperthermia in HIPEC [88–90].
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